Legend Biotech Corp. (LEGN)
15.99
-1.51
(-8.63%)
USD |
NASDAQ |
Nov 16, 16:00
16.10
+0.11
(+0.69%)
After-Hours: 20:00
Legend Biotech Shareholders Equity (Quarterly) : 1.273B for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 1.273B |
| June 30, 2026 | 1.230B |
| March 31, 2026 | 967.73M |
| December 31, 2025 | 1.002B |
| September 30, 2025 | 1.011B |
| June 30, 2025 | 1.036B |
| March 31, 2025 | 1.018B |
| December 31, 2024 | 1.041B |
| September 30, 2024 | 1.116B |
| June 30, 2024 | 1.159B |
| March 31, 2024 | 1.164B |
| December 31, 2023 | 1.251B |
| September 30, 2023 | 1.340B |
| June 30, 2023 | 1.407B |
| Date | Value |
|---|---|
| March 31, 2023 | 653.16M |
| December 31, 2022 | 744.31M |
| September 30, 2022 | |
| June 30, 2022 | 562.63M |
| March 31, 2022 | 741.16M |
| December 31, 2021 | 765.94M |
| September 30, 2021 | 225.87M |
| June 30, 2021 | 339.92M |
| March 31, 2021 | 206.46M |
| December 31, 2020 | 597.77M |
| September 30, 2020 | 334.90M |
| June 30, 2020 | 401.00M |
| March 31, 2020 | -166.33M |
| December 31, 2019 | -122.87M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 13.04B |
| Ionis Pharmaceuticals, Inc. | 393.64M |
| Cellectar Biosciences, Inc. | 22.42M |
| ACADIA Pharmaceuticals, Inc. | 1.387B |
| Alnylam Pharmaceuticals, Inc. | 3.604B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.681B |
| Total Liabilities (Quarterly) | 408.69M |
| Debt to Equity Ratio | 0.1315 |
| Current Ratio | 3.953 |
| Net Debt Paydown Yield | 1.14% |